Actos

ApprovedSmall molecule

Roche

Actos is one of 212 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

211

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

HepatitisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Multiple SclerosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Insulin ResistancePhase 2

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Diabetic RetinopathyApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Actos

Roche

Approved

4 2

Byetta

AstraZeneca

Preclinical

55 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Glargine

Eli Lilly

Preclinical

8 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Forxiga

AstraZeneca

Preclinical

3 7

Lovaza

AstraZeneca

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Acipimox

Boehringer Ingelheim

Preclinical

2 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Obesity

NCT06446531

Clinical

Trials by Indication[1]

Type 2 Diabetes4 trials

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

Terminated· Gilead logo

Gilead·Phase 2·NCT00814372·242 enrolled

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Completed· Roche logo

Roche·Phase 2·NCT00461006·176 enrolled

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

Completed· Gilead logo

Gilead·Phase 2/3·NCT00353587·396 enrolled

Show 1 more trial

A Study of Aleglitazar in Patients With Type 2 Diabetes

Completed· Roche logo

Roche·Phase 2·NCT00388518·332 enrolled

Insulin resistance1 trial

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Completed·VVA Office of Research and Development·Phase 2·NCT02278562·33 enrolled

Hepatitis1 trial

Treating Nonalcoholic Steatohepatitis With Pioglitazone

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00062764·18 enrolled

Multiple Sclerosis1 trial

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT00242177·30 enrolled

Diabetic Retinopathy1 trial

Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT01175486·200 enrolled

3 more indications

Type 2 Diabetes Mellitus1 trial

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Completed· Roche logo

Roche·Phase 2·NCT00461058·14 enrolled

Obesity1 trial

Prevention of Progression of Prediabetes, Obesity and CV Risk

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06446531·64 enrolled

Unspecified2 trials

Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649012·40 enrolled

Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00649558·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Actos. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actos compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actos. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

Actos

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Type 2 Diabetes4 trials

Insulin resistance1 trial

Hepatitis1 trial

Multiple Sclerosis1 trial

Diabetic Retinopathy1 trial

Type 2 Diabetes Mellitus1 trial

Obesity1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News